Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator TREND1, conix, MadHatter326, frosr6, KingDMC, $Pistol Pete$
Search This Board:
Last Post: 4/26/2015 8:38:41 PM - Followers: 296 - Board type: Free - Posts Today: 19

Welcome to MannKind Board!!!

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
Option Chain for MNKD
MNKD News: 10 Most Hated Companies in Healthcare 04/24/2015 08:02:03 AM
MNKD News: 3 Questions to Ask Before You Buy a Biotech Stock 04/21/2015 01:06:02 PM
MNKD News: Pain-Free Blood Tests? Sign Me Up! 04/19/2015 09:19:03 AM
MNKD News: RBC Capital Trims MannKind Target Price to $10.00 (MNKD) 04/16/2015 03:22:53 AM
MNKD News: Additional Proxy Soliciting Materials (definitive) (defa14a) 04/13/2015 06:06:41 AM
#10172  Sticky Note MNKD PF TREND1 04/20/15 04:44:52 PM
#10161  Sticky Note Can a Moratorium-delayed DTC (Direct to Consumer) Ad frosr6 04/20/15 12:55:32 AM
#10033  Sticky Note $MNKD ~ MannKind Corp. due diligence report $Pistol Pete$ 04/15/15 11:54:16 PM
#8377  Sticky Note Not Looking Good For MNKD! MadHatter326 02/13/15 02:37:35 PM
#10286   So how will MNKD pay it's short term TREND1 04/26/15 08:38:41 PM
#10285   I think these companies know more than we yosemite47 04/26/15 07:48:53 PM
#10284   I know not all Rx are accounted since frosr6 04/26/15 07:44:25 PM
#10283   Never did find the why just more of tyfoidhana 04/26/15 07:24:37 PM
#10282   a series of videos TREND1 04/26/15 07:08:11 PM
#10281   Review my previous posts for your answer. eom Denise Chanterelle 04/26/15 04:18:49 PM
#10280   Im hard pressed to understand why you find tyfoidhana 04/26/15 03:41:50 PM
#10279   I disagree with your post. Time will tell Denise Chanterelle 04/26/15 02:58:45 PM
#10278   Are you worried about MNKD going BK in TREND1 04/26/15 02:48:33 PM
#10277   As an investor Im looking to see customer tyfoidhana 04/26/15 02:37:41 PM
#10276   MNKD D TREND1 04/26/15 02:10:56 PM
#10275   That's correct Y47! You got it. Afrezza will Denise Chanterelle 04/26/15 01:52:55 PM
#10274   PRICE is the best indicator. TREND1 04/26/15 01:40:40 PM
#10273   For Investors: MNKD needs a year or two Denise Chanterelle 04/26/15 01:39:03 PM
#10272   Thanks for the info and links. I'm yosemite47 04/26/15 01:33:09 PM
#10271   GOOD POINT TREND1 04/26/15 01:26:04 PM
#10270   The truth about the RXs is soon tyfoidhana 04/26/15 12:40:23 PM
#10269   Although price is the best indicator those that TREND1 04/26/15 10:42:02 AM
#10268   Have no clue exactly how it works. frosr6 04/26/15 07:08:15 AM
#10267   Do you have any idea of what their yosemite47 04/25/15 03:47:05 PM
#10266   Well had to buy more Friday at 4.80 kugel 04/25/15 11:30:09 AM
#10265   I wonder who are these people who buy Saborte79 04/24/15 08:59:28 PM
#10264   I guess we will see what we see. Phaeton 04/24/15 08:10:41 PM
#10263   *** Phaeton TREND1 04/24/15 07:51:15 PM
#10262   I guess that I need to be ready Phaeton 04/24/15 07:32:08 PM
#10261   Mahalo Clay. eom Denise Chanterelle 04/24/15 05:07:30 PM
#10260   * * $MNKD Video Chart 04-24-15 * * ClayTrader 04/24/15 04:55:15 PM
#10259   I'm not disagreeing with you on that. yosemite47 04/24/15 04:07:56 PM
#10258   For Investors: Early results coming in indicate that Denise Chanterelle 04/24/15 03:09:41 PM
#10257   From what I've read most Rx are 90 frosr6 04/24/15 03:02:50 PM
#10256   There are 2 sets of numbers (TRX NRX) frosr6 04/24/15 02:49:55 PM
#10255   SNY'S 1200 REPS CAN NOT SAY Afrezza will TREND1 04/24/15 02:43:54 PM
#10254   Wait until the 90-day AC1 counts come back Denise Chanterelle 04/24/15 02:26:58 PM
#10253   Maybe I didn't fully understand the partnership between yosemite47 04/24/15 01:51:18 PM
#10252   part of my morning routine is checking my yosemite47 04/24/15 01:33:59 PM
#10251   What if afrezza crosses below Exubera? TREND1 04/24/15 01:22:00 PM
#10250   Got my $4.70's call right on the money. KingDMC 04/24/15 01:02:07 PM
#10249   For Investors: Rx counts are meaningless at this Denise Chanterelle 04/24/15 12:49:49 PM
#10248   new RX'S = 210 TREND1 04/24/15 12:31:40 PM
#10247   MNKD has new low Today TREND1 04/24/15 12:24:07 PM
#10246   10 Most Hated Companies in Healthcare TREND1 04/24/15 12:20:20 PM
#10245   I do believe with an additional 50 to tyfoidhana 04/24/15 11:14:20 AM
#10244   NRX 210 frosr6 04/24/15 08:55:38 AM
#10243   Don't know anyone that can call a winner kugel 04/24/15 08:35:20 AM
#10242   Nice find. Afrezza in action! Mahalo for posting. eom Denise Chanterelle 04/24/15 02:38:09 AM
#10241   Clinical Results of an Automated Artificial Pancreas Using COO2002COO 04/24/15 01:38:42 AM
#10240   Absolutely. Traders on the contrary use this COO2002COO 04/24/15 01:36:34 AM
#10239   To those who have Invested in MNKD: Rx Denise Chanterelle 04/24/15 12:57:46 AM
#10238   *****For Investors: Rx count is VERY IMPORTANT TREND1 04/24/15 12:42:03 AM
#10237   And GL to you RF2! Aloha. eom Denise Chanterelle 04/24/15 12:32:37 AM